Head to head
PlushCare vs Ro: Pricing, Evidence and What Neither Discloses
$319 against $348 is a 8% difference between two figures neither of which we captured ourselves. That gap is smaller than the uncertainty in the figures, so we do not call a winner.
Neither PlushCare nor Ro Body gives a compounded tirzepatide price we could compare: PlushCare sells brand-name drugs, not compounded tirzepatide, and Ro Body could not be read on November 20–21, 2026. On our written v4.1 scoring guide, PlushCare scores 65/100 (#13 of 22) and Ro Body is not scored.
The short answer
$319 against $348 is a 8% difference between two figures neither of which we captured ourselves. That gap is smaller than the uncertainty in the figures, so we do not call a winner. Both figures are provider-reported.
Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.
Compare at a maintenance dose, not at signup
The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.
Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.
What neither has told us
Neither PlushCare nor Ro has named its fulfilling pharmacy or its registration class. That is true of most providers in our dataset (NexLife’s plan pages do name three 503A pharmacies), and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.
The comparison that outranks both
Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.
Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.
Show this figure as a table
| Item | PlushCare | Ro |
|---|---|---|
| Tirzepatide | $319 | not captured |
| Semaglutide | not captured | $348 |
| Field | PlushCare | Ro |
|---|---|---|
| Lowest captured all-in | $319/mo | $348/mo |
| Lowest tirzepatide | $319/mo | not verified |
| Lowest semaglutide | not verified | $348/mo |
| Records we hold | 1 | 1 |
| Evidence status | Provider-reported Provider-reported | Provider-reported Provider-reported |
| Fulfilling pharmacy named to us | no | no |
| Registration class disclosed | no | no |
| State availability verified | no | no |
| Cancellation terms captured | not verified | not verified |
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| PlushCare | month_to_month | brand injectable, FDA-approved | not recorded | $319 | not verified | $319 | Recurring | Provider-reported | 2026-07-06 |
| Ro | month_to_month | brand injectable, FDA-approved | not recorded | $348 | not verified | $348 | Recurring | Provider-reported | 2026-07-06 |
Our editorial pick, NexLife, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan (as of November 20, 2026), the same price at every dose with no membership fee. See NexLife’s current plans.
Questions readers actually ask
Is PlushCare cheaper than Ro?
Neither PlushCare nor Ro Body gives a compounded tirzepatide price we could compare: PlushCare sells brand-name drugs, not compounded tirzepatide, and Ro Body could not be read on November 20–21, 2026.
Why is one marked verified and the other reported?
On our written v4.1 scoring guide, PlushCare scores 65/100 (#13 of 22) and Ro Body is not scored. The scores come from each program’s own pages and FDA’s warning-letter index, read November 20–21, 2026.
Does either name its pharmacy?
PlushCare: Prescriptions sent to any local pharmacy of your choice (brand drugs). Ro Body: not read.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
Related coverage
- OrderlyMeds vs Zappy Health
- Every provider comparison
- All provider reviews
- What a year actually costs
- Flat-rate pricing explained
- Trial reviews
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Three Years of Tirzepatide Markedly Reduced Progression to Type 2 Diabetes in Prediabetes
GLP-1 Tirzepatide Review. “PlushCare vs Ro: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/compare/plushcare-vs-ro-body/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.